
Christine J. Saoud
Examiner (ID: 4595)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1616, 1801, 1812, 1647, 1646, 1645, 2899 |
| Total Applications | 1543 |
| Issued Applications | 747 |
| Pending Applications | 209 |
| Abandoned Applications | 630 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10838195
[patent_doc_number] => 08865871
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-10-21
[patent_title] => 'Antibodies and kits for immunodetection of epitope tags'
[patent_app_type] => utility
[patent_app_number] => 13/302136
[patent_app_country] => US
[patent_app_date] => 2011-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 23
[patent_no_of_words] => 12190
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13302136
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/302136 | Antibodies and kits for immunodetection of epitope tags | Nov 21, 2011 | Issued |
Array
(
[id] => 9016322
[patent_doc_number] => 20130231286
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-09-05
[patent_title] => 'Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer'
[patent_app_type] => utility
[patent_app_number] => 13/988014
[patent_app_country] => US
[patent_app_date] => 2011-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 8344
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13988014
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/988014 | Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer | Nov 15, 2011 | Abandoned |
Array
(
[id] => 8211161
[patent_doc_number] => 20120129766
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-24
[patent_title] => 'METHODS OF TREATING FGF21-ASSOCIATED DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 13/296343
[patent_app_country] => US
[patent_app_date] => 2011-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 28276
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0129/20120129766.pdf
[firstpage_image] =>[orig_patent_app_number] => 13296343
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/296343 | Fibroblast growth factor 21 mutations | Nov 14, 2011 | Issued |
Array
(
[id] => 10906154
[patent_doc_number] => 20140309167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-16
[patent_title] => 'COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF ACUTE KIDNEY INJURY'
[patent_app_type] => utility
[patent_app_number] => 14/353236
[patent_app_country] => US
[patent_app_date] => 2011-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1916
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14353236
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/353236 | COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF ACUTE KIDNEY INJURY | Nov 8, 2011 | Abandoned |
Array
(
[id] => 9468994
[patent_doc_number] => 08722622
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-05-13
[patent_title] => 'FGF21 conjugates and anti-diabetic uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/289533
[patent_app_country] => US
[patent_app_date] => 2011-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 48
[patent_no_of_words] => 34408
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13289533
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/289533 | FGF21 conjugates and anti-diabetic uses thereof | Nov 3, 2011 | Issued |
Array
(
[id] => 7711821
[patent_doc_number] => 20120004173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-05
[patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING SKIN AGING AND SCARS'
[patent_app_type] => utility
[patent_app_number] => 13/233315
[patent_app_country] => US
[patent_app_date] => 2011-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 5892
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13233315
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/233315 | Method for treating skin aging by administration of bFGF | Sep 14, 2011 | Issued |
Array
(
[id] => 10353565
[patent_doc_number] => 20150238570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-08-27
[patent_title] => 'THERAPEUTIC AGENT FOR HYPERTHERMIA'
[patent_app_type] => utility
[patent_app_number] => 14/002570
[patent_app_country] => US
[patent_app_date] => 2011-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 10151
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14002570
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/002570 | Methods of lowering body temperature by administration of desacyl ghrelin or its derivative | Sep 1, 2011 | Issued |
Array
(
[id] => 8381463
[patent_doc_number] => 20120225081
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-09-06
[patent_title] => 'VEGF-BINDING MOLECULES'
[patent_app_type] => utility
[patent_app_number] => 13/223563
[patent_app_country] => US
[patent_app_date] => 2011-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 26334
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13223563
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/223563 | VEGF-BINDING MOLECULES | Aug 31, 2011 | Abandoned |
Array
(
[id] => 9496725
[patent_doc_number] => 08735539
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-05-27
[patent_title] => 'Relaxin polypeptides comprising non-naturally encoded amino acids'
[patent_app_type] => utility
[patent_app_number] => 13/212101
[patent_app_country] => US
[patent_app_date] => 2011-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 42
[patent_no_of_words] => 103938
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13212101
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/212101 | Relaxin polypeptides comprising non-naturally encoded amino acids | Aug 16, 2011 | Issued |
Array
(
[id] => 9496725
[patent_doc_number] => 08735539
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-05-27
[patent_title] => 'Relaxin polypeptides comprising non-naturally encoded amino acids'
[patent_app_type] => utility
[patent_app_number] => 13/212101
[patent_app_country] => US
[patent_app_date] => 2011-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 42
[patent_no_of_words] => 103938
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13212101
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/212101 | Relaxin polypeptides comprising non-naturally encoded amino acids | Aug 16, 2011 | Issued |
Array
(
[id] => 9496725
[patent_doc_number] => 08735539
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-05-27
[patent_title] => 'Relaxin polypeptides comprising non-naturally encoded amino acids'
[patent_app_type] => utility
[patent_app_number] => 13/212101
[patent_app_country] => US
[patent_app_date] => 2011-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 42
[patent_no_of_words] => 103938
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13212101
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/212101 | Relaxin polypeptides comprising non-naturally encoded amino acids | Aug 16, 2011 | Issued |
Array
(
[id] => 9496725
[patent_doc_number] => 08735539
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-05-27
[patent_title] => 'Relaxin polypeptides comprising non-naturally encoded amino acids'
[patent_app_type] => utility
[patent_app_number] => 13/212101
[patent_app_country] => US
[patent_app_date] => 2011-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 42
[patent_no_of_words] => 103938
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13212101
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/212101 | Relaxin polypeptides comprising non-naturally encoded amino acids | Aug 16, 2011 | Issued |
Array
(
[id] => 8738281
[patent_doc_number] => 08410051
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-04-02
[patent_title] => 'FGF21 mutants and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/196544
[patent_app_country] => US
[patent_app_date] => 2011-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 89
[patent_figures_cnt] => 89
[patent_no_of_words] => 32440
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13196544
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/196544 | FGF21 mutants and uses thereof | Aug 1, 2011 | Issued |
Array
(
[id] => 8854140
[patent_doc_number] => 20130143815
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-06-06
[patent_title] => 'GROWTH HORMONE CONJUGATES'
[patent_app_type] => utility
[patent_app_number] => 13/809681
[patent_app_country] => US
[patent_app_date] => 2011-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 39673
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13809681
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/809681 | GROWTH HORMONE CONJUGATES | Jul 14, 2011 | Abandoned |
Array
(
[id] => 8670699
[patent_doc_number] => 20130045237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-02-21
[patent_title] => 'Combination pharmaceutical composition and methods of treating and preventing the infectious diseases'
[patent_app_type] => utility
[patent_app_number] => 13/135899
[patent_app_country] => US
[patent_app_date] => 2011-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 23939
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13135899
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/135899 | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | Jul 14, 2011 | Abandoned |
Array
(
[id] => 8976609
[patent_doc_number] => 20130210039
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-08-15
[patent_title] => 'BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES'
[patent_app_type] => utility
[patent_app_number] => 13/819704
[patent_app_country] => US
[patent_app_date] => 2011-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 14905
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13819704
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/819704 | BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES | Jul 12, 2011 | Abandoned |
Array
(
[id] => 8063091
[patent_doc_number] => 20110245471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-10-06
[patent_title] => 'NUCLEAR FACTOR kappaB INDUCING FACTOR'
[patent_app_type] => utility
[patent_app_number] => 13/157798
[patent_app_country] => US
[patent_app_date] => 2011-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 21137
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0245/20110245471.pdf
[firstpage_image] =>[orig_patent_app_number] => 13157798
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/157798 | Nuclear factor κB inducing factor | Jun 9, 2011 | Issued |
Array
(
[id] => 9055170
[patent_doc_number] => 20130252884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-09-26
[patent_title] => 'FGF21 ANALOGUES AND DERIVATIVES'
[patent_app_type] => utility
[patent_app_number] => 13/702122
[patent_app_country] => US
[patent_app_date] => 2011-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11884
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13702122
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/702122 | FGF21 ANALOGUES AND DERIVATIVES | Jun 5, 2011 | Abandoned |
Array
(
[id] => 7767838
[patent_doc_number] => 20120035099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-09
[patent_title] => 'FGF21 ANALOGUES AND DERIVATIVES'
[patent_app_type] => utility
[patent_app_number] => 13/154081
[patent_app_country] => US
[patent_app_date] => 2011-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11801
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0035/20120035099.pdf
[firstpage_image] =>[orig_patent_app_number] => 13154081
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/154081 | FGF21 ANALOGUES AND DERIVATIVES | Jun 5, 2011 | Abandoned |
Array
(
[id] => 7756688
[patent_doc_number] => 20120028896
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-02
[patent_title] => 'USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS'
[patent_app_type] => utility
[patent_app_number] => 13/152750
[patent_app_country] => US
[patent_app_date] => 2011-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 64341
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0028/20120028896.pdf
[firstpage_image] =>[orig_patent_app_number] => 13152750
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/152750 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | Jun 2, 2011 | Abandoned |